Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 10, 2009, Pages 4385-4392

  Pham, P A ^a,e   La Porte, C J L ^b   Lee, L S ^a   Van Heeswijk, R ^b,f   Sabo, J P ^c   Elgadi, M M ^d   Piliero, P J ^c   Barditch Crovo, P ^a   Fuchs, E ^a   Flexner, C ^a   Cameron, D W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^d BOEHRINGER INGELHEIM CANADA LTD   (Canada)

^e Tibotec BVBA ^*  (United States)

^f TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; RITONAVIR PLUS TIPRANAVIR; ROSUVASTATIN;

ABDOMINAL CRAMP; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GEOMETRY; HEADACHE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NAUSEA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRIDINES; PYRIMIDINES; PYRONES; PYRROLES; RITONAVIR; SULFONAMIDES; YOUNG ADULT;

EID: 70349495858     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00449-09     Document Type: Article

References (28)

1. American Heart Association. 2002. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421.
2. Busti, A. J., A. M. Bain, R. G. Hall II, R. G. Bedimo, R. D. Leff, C. Meek, and R. Mehvar. 2008. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J. Cardiovasc. Pharmacol. 51:605-610.
3. Castro, J. G., and L. Gutierrez. 2002. Rhabdomyolysis with acute renal failure probably related to the interaction of atorvastatin and delavirdine. Am. J. Med. 112:505.
4. Fetsch, P. A., A. Abati, T. Litman, K. Morisaki, Y. Honjo, K. Mittal, and S. E. Bates. 2006. Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissues. Cancer Lett. 235:84-92.
5. Fichtenbaum, C. J., J. G. Gerber, S. L. Rosenkranz, Y. Segal, J. A. Aberg, T. Blaschke, B. Alston, F. Fang, B. Kosel, and F. Aweeka. 2002. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16:569-577.
6. Gutmann, H., P. Hruz, C. Zimmermann, C. Beglinger, and J. Drewe. 2005. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochem. Pharmacol. 70:695-699.
7. Hagenbuch, B., and P. J. Meier. 2003. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609:1-18.
8. Hermann, M., A. Asberg, H. Christensen, H. Holdaas, A. Hartmann, and J. L. Reubsaet. 2004. Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin. Pharmacol. Ther. 76:388-391.
9. Hicks, C. B., P. Cahn, D. A. Cooper, S. L. Walmsley, C. Katlama, B. Clotet, A. Lazzarin, M. A. Johnson, D. Neubacher, D. Mayers, and H. Valdez. 2006. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 368:466-475.
10. Hirano, M., K. Maeda, Y. Shitara, and Y. Sugiyama. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311:139-146.
11. Hsyu, P. H., M. D. Schultz-Smith, J. H. Lillibridge, R. H. Lewis, and B. M. Kerr. 2001. Pharmacokinetic interactions between nelfinavir and 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob. Agents Chemother. 45:3445-3450.
12. Huang, L., Y. Wang, and S. Grimm. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab. Dispos. 34:738-742.
13. Keskitalo, J. E., O. Zolk, M. F. Fromm, K. J. Kurkinen, P. J. Neuvonen, and M. Niemi. 2009. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin. Pharmacol. Ther. 86:197-203.
14. Kiser, J. J., J. G. Gerber, J. A. Predhomme, P. Wolfe, D. M. Flynn, and D. W. Hoody. 2008. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J. Acquir. Immune Defic. Syndr. 47:570-578.
15. Lennernäs, H. 2003. Clinical pharmacokinetics of atorvastatin. Clin. Pharmacokinet. 42:1141-1160.
16. MacGregor, T. R., J. P. Sabo, S. H. Norris, P. Johnson, L. Galitz, and S. McCallister. 2004. Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers. HIV Clin. Trials 5:371-382.
17. Maliepaard, M., G. L. Scheffer, I. F. Faneyte, M. A. van Gastelen, A. C. Pijnenborg, A. H. Schinkel, M. J. van De Vijver, R. J. Scheper, and J. H. Schellens. 2001. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61: 3458-3464. (Pubitemid 32695041)
18. Maltz, H. C., D. L. Balog, and J. S. Cheigh. 1999. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine. Ann. Pharmacother. 33:1176-1179.
19. Matsson, P., G. Englund, G. Ahlin, C. A. Bergstrom, U. Norinder, and P. Artursson. 2007. A global drug inhibition pattern for the human ATPbinding cassette transporter breast cancer resistance protein (ABCG2). J. Pharmacol. Exp. Ther. 323:19-30.
20. Merino, G., J. W. Jonker, E. Wagenaar, A. E. van Herwaarden, and A. H. Schinkel. 2005. The breast cancer resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol. 67:1758-1764.
21. Omar, M. A., and J. P. Wilson. 2002. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36:288-295.
22. Penzak, S. R., J. M. Shen, R. M. Alfaro, A. T. Remaley, V. Natarajan, and J. Falloon. 2004. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther. Drug Monit. 26:322-330.
23. Posvar, E. L., L. L. Radulovic, D. D. Cilla, Jr., L. R. Whitfield, and A. J. Sedman. 1996. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J. Clin. Pharmacol. 36:728-731.
24. Simonson, S. G., A. Raza, P. D. Martin, P. D. Mitchell, J. A. Jarcho, C. D. Brown, A. S. Windass, and D. W. Schneck. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76:167-177.
25. Tirona, R. G., B. F. Leake, A. W. Wolkoff, and R. B. Kim. 2003. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304:223-228.
26. van Heeswijk, R. P., A. Veldkamp, J. W. Mulder, P. L. Meenhorst, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2001. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir. Ther. 6:201-229.
27. Weiss, J., J. Rose, C. H. Storch, N. Ketabi-Kiyanvash, A. Sauer, W. E. Haefeli, and T. Efferth. 2007. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother. 59:238-245.
28. Ye, Z. W., P. Augustijns, and P. Annaert. 2008. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab. Dispos. 36:1315-1321.